التداخل بين أبيراتيرون وديكساميثازون

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid.

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment.

Avoid concomitant strong CYP3A4 inducers during Abiraterone Acetate treatment.

Increased dosage of corticosteroids may be indicated before, during and after stressful situations.

Monitor patients for symptoms and signs of adrenocortical insufficiency, particularly if patients are withdrawn from corticosteroids, have corticosteroid dose reductions, or experience unusual stress.